Crossmark

HER2-low breast cancer in routine practice: a nationwide study of diagnostic variability across pathology laboratories

Published Online: 2025-09-16

Authors

Kain, Zeynep E. https://orcid.org/0000-0003-0092-2884
Baez-Navarro, Ximena

’t Hart, Nils A.

van Deurzen, Carolien H. M.
License Information

Text and Data Mining valid from 2025-09-16

Version of Record valid from 2025-09-16
More Information

Article History

Received: 14 July 2025

Revised: 25 August 2025

Accepted: 4 September 2025

First Online: 16 September 2025

Declarations

:

: According to the Code of Conduct of the Federation of Medical Sciences in the Netherlands, no informed consent or ethical approval was needed for this study. This study was performed following the Declaration of Helsinki.

: C. van Deurzen received research funding from Roche and AstraZeneca. She participated in an advisory board for MSD.N. ‘t Hart received research funding from AstraZeneca, MSD and Roche. He participated in advisory boards for Amgem, AstraZeneca and Daiichi-Sankyo.These disclosures are all unrelated to this work. For this project, we did not receive any funding.The other authors have no relevant financial or non-financial interests to disclose.

Document is current